Published in Volume
124, Issue 7
(July 1, 2014)J Clin Invest.
Copyright © 2014, American Society for Clinical
Umbilical cord blood expansion with nicotinamide provides long-term
1Adult Blood and Marrow Transplant Program, Duke University
Medical Center, Durham, North Carolina, USA.
2Loyola University Medical
Center, Maywood, Illinois, USA.
3The EMMES Corporation, Rockville, Maryland,
4Goldyne Savad Institute of Gene Therapy, Hadassah - Hebrew University
Medical Center, Jerusalem, Israel.
5Gamida Cell Ltd., Jerusalem, Israel.
6Pediatric Blood and Marrow Transplant Program, Duke University Medical
Center, Durham, North Carolina, USA.
Address correspondence to: Mitchell E. Horwitz, Duke University School of Medicine,
2400 Pratt St., DUMC 3961, Durham, North Carolina 27710, USA. Phone: 919.668.1045; Fax:
919.668.1091; E-mail: firstname.lastname@example.org.
First published June 9, 2014
Submitted: January 7,
2014; Accepted: April 17,
BACKGROUND. Delayed hematopoietic recovery is a major drawback of
umbilical cord blood (UCB) transplantation. Transplantation of ex vivo–expanded UCB
shortens time to hematopoietic recovery, but long-term, robust engraftment by the expanded
unit has yet to be demonstrated. We tested the hypothesis that a UCB-derived cell product
consisting of stem cells expanded for 21 days in the presence of nicotinamide and a
noncultured T cell fraction (NiCord) can accelerate hematopoietic recovery and provide
METHODS. In a phase I trial, 11 adults with hematologic malignancies
received myeloablative bone marrow conditioning followed by transplantation with NiCord
and a second unmanipulated UCB unit. Safety, hematopoietic recovery, and donor engraftment
were assessed and compared with historical controls.
RESULTS. No adverse events were attributable to the infusion of NiCord.
Complete or partial neutrophil and T cell engraftment derived from NiCord was observed in
8 patients, and NiCord engraftment remained stable in all patients, with a median
follow-up of 21 months. Two patients achieved long-term engraftment with the unmanipulated
unit. Patients transplanted with NiCord achieved earlier median neutrophil recovery (13
vs. 25 days, P < 0.001) compared with that seen in historical
controls. The 1-year overall and progression-free survival rates were 82% and 73%,
CONCLUSION. UCB-derived hematopoietic stem and progenitor cells expanded
in the presence of nicotinamide and transplanted with a T cell–containing fraction
contain both short-term and long-term repopulating cells. The results justify further
study of NiCord transplantation as a single UCB graft. If long-term safety is confirmed,
NiCord has the potential to broaden accessibility and reduce the toxicity of UCB
TRIAL REGISTRATION. Clinicaltrials.gov NCT01221857.
FUNDING. Gamida Cell Ltd.
Delayed hematopoietic and immunologic recovery, graft failure, and graft versus host
disease (GVHD) all contribute to transplant-related mortality in adult recipients of
umbilical cord blood (UCB) transplantation (1–5). Cell dose and HLA matching are
critical determinants of a successful outcome (6–9). For patients without a single
UCB unit with adequate cell dose, dual UCB transplantation is an acceptable alternative
(10). Yet, the problem of delayed hematopoietic
recovery persists, leading to longer hospitalization and increased resource utilization. Ex
vivo expansion of hematopoietic stem and progenitor cells (HSPCs) is a modality that could
address these limitations of cord blood transplantation. If short-term and long-term HSPCs
could be expanded ex vivo from UCB, then prompt and durable hematopoietic recovery after
transplantation of a single UCB unit could be achieved in the majority of patients. Recently
reported cord blood expansion studies have demonstrated the contribution of expanded cells
to short-term engraftment, while long-term engraftment came from the coinfused second
unmanipulated unit (11, 12).
NiCord is an ex vivo–expanded cell product derived from UCB that uses a small
molecule, nicotinamide, as the active agent that inhibits differentiation and enhances the
functionality of HSPCs expanded in ex vivo cultures. When nicotinamide is added to
stimulatory hematopoietic cytokines, UCB-derived hematopoietic progenitor cell cultures
demonstrate an increased frequency of phenotypically primitive
CD34+CD38– cells and a decreased frequency of
lineage-committed progenitor cells. The cells expanded in culture with nicotinamide
demonstrate increased migration toward stromal cell–derived factor 1 and increased
homing to the bone marrow, resulting in enhanced engraftment efficiency (13).
Double UCB transplantation provides a safe clinical experimental model to demonstrate the
existence of short- and long-term repopulating hematopoietic stem cells as well as the
clinical benefit of an ex vivo–expanded graft. We report here results of a phase I
trial testing the hypothesis that NiCord can safely provide HSPCs that are capable of
producing rapid and durable hematopoietic engraftment in adult recipients of myeloablative
Patients. Twelve patients (Duke University Medical Center, 11 patients; Loyola University Medical
Center, 1 patient) were enrolled in the study (Figure 1). One patient was successfully transplanted with a single unmanipulated cord
blood unit, because the NiCord unit failed to meet release criteria (initial gram-positive
stain, later deemed to be a false-positive). This patient was excluded from outcome
analysis. Table 1 shows the characteristics of the
11 evaluable study patients and the 17 Duke historical control patients (14). All patients had hematologic malignancies in
either complete or partial remission and received 1,350 cGy total body irradiation (TBI)
as part of the conditioning regimen.
CONSORT diagram for this phase I nonrandomized trial.
Patient and graft characteristics
Graft characteristics. Table 2 shows the cell doses of the unmanipulated
and NiCord-designated UCB units before cryopreservation, as reported by the cord blood
bank, and the cell doses and graft characteristics at the time of infusion. The median
total nucleated cell dose of the unmanipulated unit and the NiCord unit was 2.6 ×
107 (range, 1.9 × 107 to 4.3 × 107) per
kilogram of the recipient’s body weight and 2.5 × 107 (range, 1.7
× 107 to 3.8 × 107) per kilogram of the recipient’s
body weight, respectively (P = 0.28). The median CD34+ cell
dose at the time of cryopreservation of the unmanipulated unit was 0.12 ×
106 (range, 0.03 × 106 to 0.23 × 106) per
kilogram of the recipient’s body weight and 0.17 × 106 (range, 0.05
× 106 to 0.35 × 106) per kilogram of the
recipient’s body weight (P = 0.40) for the NiCord unit. The
CD133+ fraction of the NiCord unit was cultured for 21 days, resulting in a
median 486-fold expansion (range, 171–643) of the nucleated cells. When combined
with the noncultured CD133– fraction, the median final infused total
nucleated cell dose was 3.1 × 107 per kilogram. NiCord expansion resulted
in a median 72-fold (range, 16–186) expansion of CD34+ cells, providing
a median infused CD34+ cell dose of 3.5 × 106 (range, 0.9
× 106 to 18.3 × 106) per kilogram. The median infused
CD34+ cell dose from the unmanipulated unit was 0.07 × 106
(range, 0.03 × 106 to 0.48 × 106) per kilogram. The
CD3+ cell dose from the NiCord unit was derived entirely from the noncultured
CD133– fraction. As a consequence of multiple manipulations, the
median CD3+ cell dose from the NiCord unit was 1.3 × 106
(range, 0.49 × 106 to 5.81 × 106) per kilogram, which was
significantly lower than the median cell dose from the manipulated unit of 3.4 ×
106 (range, 1.9 × 106 to 4.7 × 106) per
kilogram (P = 0.009). Of note, the infused CD3+ cell dose was
not directly measured; instead, it was estimated based on the experience accumulated
during product development, which demonstrated a median 70% recovery after thawing.
Graft characteristics of unmanipulated and NiCord cord blood grafts
Chimerism analysis. Figure 2 shows the pattern of engraftment within the
CD15+ myeloid cell and CD3+ T cell fractions from peripheral blood
for the 10 patients who were engrafted with donor cells. Patient 10 demonstrated 100%
NiCord donor chimerism in samples collected from unfractionated whole blood through the
final day of assessment (day 42). Lineage-specific chimerism was not available; however,
it is assumed that the observed NiCord-derived cells were predominantly myeloid cells,
given the early time points at which they were collected. Eight patients (patients 1, 2,
3, 6, 7, 9, 10, and 11) demonstrated a persistent presence of NiCord-derived myeloid cells
ranging from 41% to 100%. Stable engraftment of T cells derived from the NiCord unit was
also observed in 6 patients (patients 2, 3, 6, 7, 9, and 11). Mixed hematopoietic
chimerism (donor-donor or donor-host) was more common in the T cell fraction. In all
surviving patients, NiCord engraftment has remained stable for up to 36 months, suggesting
engraftment of NiCord-derived HSPCs. Two patients (patients 4 and 5) achieved long-term
engraftment that was exclusively from the unmanipulated unit. One patient (patient 8)
failed to engraft and was successfully rescued with a second transplant from a
haploidentical donor. The infusion order of NiCord and the unmanipulated unit did not
correlate with the pattern of engraftment.
Myeloid (CD15+) and T cell (CD3+) chimerism measurements
following transplantation. Bars demonstrate the median percentage of cells derived from the NiCord unit, the
unmanipulated unit, and the host at serial time points following transplantation.
Patient 8 experienced primary graft failure and was excluded. Whole-blood chimerism
analysis was performed on samples from patient 10, showing 100% NiCord engraftment.
Patients were censored at the time of documented relapse or death. *Whole-blood
chimerism analysis demonstrated 100% NiCord engraftment.
Hematopoietic recovery. The kinetics of white blood cell count recovery and the median time to neutrophil
recovery are demonstrated in Figure 3A. For all
patients transplanted with NiCord, neutrophil recovery was achieved in 13 days (range,
7–26 days) versus 25 days (range, 13–38 days) in the Duke historical cohort
(P < 0.001). The median time to neutrophil recovery for the 8
patients engrafted with NiCord was 11 days (range, 7–18 days). At later time points
out to 2 years, we found no significant difference in the white blood cell count of the
study patients or of the Duke controls (Figure 3B).
Hematopoietic recovery following transplantation. (A) Early white blood cell recovery with associated neutrophil engraftment
and (B) durability of white blood cell count at late time points in
patients transplanted with NiCord and in a historical control cohort. Bars represent the
interquartile range. (C) Early platelet recovery and (D)
durability of platelet count at late time points in patients transplanted with NiCord
and in a historical control cohort. The historical control patients were transplanted
with 2 unmanipulated UCB units.
The median time to platelet engraftment was 33 days (range, 26–49 days) for all
patients transplanted with NiCord and 37 days (range, 20–66 days) for the Duke
historical control cohort (P = 0.085) (Figure 3C). Platelet recovery occurred on median day 30 (range, 26–41)
for the 7 patients who demonstrated engraftment with NiCord. Patient 10 died before
achieving platelet recovery, and patient 8 experienced primary engraftment failure. At
later time points out to 2 years, we observed no significant difference in the platelet
counts of study patients or of Duke controls (Figure 3D). We have observed no secondary graft failure to date in any of the patients
who achieved donor engraftment from either the unmanipulated or the NiCord-expanded cord
For patients who were engrafted with the NiCord-expanded cord blood unit, the number of
total nucleated cells contained within the product correlated with the speed of both
neutrophil (Spearman’s correlation coefficient, –0.86; P =
0.006) and platelet engraftment (Spearman’s correlation coefficient, –0.77;
P = 0.04). The number of CD34+ cells in the NiCord product
also correlated with the speed of neutrophil (Spearman’s correlation coefficient,
r = –0.82; P = 0.01) and platelet
(Spearman’s correlation coefficient, r = –0.77;
P = 0.04) engraftment.
Transplantation course and outcome. Transplantation course and outcome are summarized in Table 3. One grade III adverse event (hypertension) and no grades IV/V adverse
events were attributable to infusion of the NiCord UCB graft. The median duration of
initial hospitalization for all study patients was 26 days (range, 17–57 days).
Clinical outcome of transplantation
We observed acute grade II GVHD in 5 patients and no cases of acute grades III/IV GVHD.
Two patients developed chronic GVHD, 2 patients (patients 3 and 9) died of relapsed
disease, and 1 patient (patient 10) died of pneumonia. With a median follow-up of 21
months, the 1-year overall and progression-free survival rates were 82% and 73%,
respectively (Figure 4).
Overall and event-free survival. Overall and event-free survival for all subjects who received NiCord-expanded UCB stem
Based on preclinical work suggesting that HSPCs with increased capacity for bone marrow
migration, homing, and engraftment can be expanded from UCB using NiCord technology (13), we performed a phase I clinical trial to confirm
this observation. Using the myeloablative double cord blood transplantation approach (15, 16), we
transplanted 1 unmanipulated unit and a second unit in which a CD133+ fraction
was cultured ex vivo for 3 weeks and infused with a small, uncultured T cell fraction. The
cultured unit provided long-term engraftment in 8 of 10 evaluable patients. The novel
finding of this trial is that an expanded UCB graft is capable of outcompeting an
unmanipulated cord blood graft and of providing both rapid engraftment and robust,
multilineage hematopoiesis for more than 2 years.
Following dual UCB transplantation, hematopoiesis is ultimately provided by a single UCB
unit in nearly all cases. Factors that predict the dominant unit have yet to be fully
characterized, but there is evidence that an immunologic “graft versus graft”
reaction is initiated following transplantation that culminates in the elimination of the
immunologically nondominant unit (17, 18). Nicotinamide, the active molecule of NiCord
expansion technology, slows down differentiation of proliferating early progenitor cells,
thus enhancing expansion of primitive progenitor cells
CD34+CD38–Lin–) (13). The expanded fraction provides robust myeloid and T cell engraftment
in immune-deficient NOD/SCID/IL-2 receptor γ chain knockout (NSG) mice for more than 6
months (data not shown). However, NiCord culture conditions do not support the expansion of
mature lymphoid cells. To compensate for this immunologic disadvantage, we coinfused the
CD133– noncultured fraction of the NiCord unit, cryopreserved after
selection, that contained a portion of the original graft’s immunocompetent T cells
and NK cells. Our hypothesis, which will need to be experimentally proven, is that this
fraction provides support to NiCord-cultured HSPCs. This support, in combination with an
enhanced HSPC dose following ex vivo expansion, allows NiCord to compete successfully for
engraftment. Furthermore, the CD133– fraction provides the substrate for
early cellular immune recovery via peripheral T cell expansion in the lymphodepleted host
Patients engrafted with NiCord were transplanted with a smaller T cell fraction compared
with those receiving conventional single or dual UCB transplantation. As a result, there was
a theoretic potential for compromised immunologic recovery in recipients with predominantly
NiCord-derived donor chimerism. While the sample size was too small to draw firm
conclusions, we were unable to detect quantitative differences in T cell, NK cell, B cell,
or T cell receptor excision circle–positive cell (TREC) recovery between patients
engrafted solely with the NiCord unit and those who received conventional dual UCB
transplantation. Of note, 2 patients (patients 7 and 9) who were engrafted with the NiCord
unit had prolonged dual cord blood T cell chimerism. Such a phenomenon was not observed in
the control cohort. Interestingly, these 2 patients received cord blood units that were
matched at 5 of 6 HLA loci. This was the highest degree of inter–cord blood matching
among all study patients. The significance of this observation will require a larger study
The existence of CD34–, highly primitive HSPCs with long-term
repopulating potential demonstrated in immunodeficient mice has been described (21, 22). The
presence of these cells in a CD133– fraction has been neither confirmed
nor refuted, raising the possibility that this nonexpanded fraction contributes to long-term
engraftment of NiCord. We have transplanted high numbers of CD133– cells
into NOD/SCID mice as well as CD133–/CD3– cells into NSG
mice and found no evidence of myeloid engraftment during a 6-month follow-up period (data
not shown). Therefore, given the low cell dose of the transplanted CD133–
fraction and the uncertain existence of long-term repopulating cells following CD133
depletion, the participation of this fraction in long-term engraftment we observed in NiCord
recipients is unlikely, but cannot be ruled out.
This study is similar in design to 2 recently published studies of ex vivo–expanded
cord blood HSPCs transplanted along with a second unmanipulated UCB unit. In the first of
these trials, Delaney and colleagues transplanted cord blood that was enriched for
CD34+ cells and expanded for 16 days in culture flasks or bags that were coated
with Notch ligand (11). In the second study by de
Lima and colleagues, cord blood cells were cocultured for 14 days in flasks containing
adherent mesenchymal precursor cells (12). In
contrast to the present study, the expanded unit from these earlier studies was not
supplemented with an infusion of immunocompetent T cells. The data from these studies
clearly show that transplantation of ex vivo–cultured UCB stem cells shortens the
time to hematopoietic recovery following myeloablative chemotherapy. This is accomplished by
increasing the frequency of lineage-committed short-term repopulating hematopoietic stem
cells (11, 12). However, 6 months after transplantation, hematopoiesis derived from the
expanded unit was negligible. In all cases, the coinfused unmanipulated cord blood unit
provided long-term hematopoiesis. There are two potential explanations for the lack of
long-term engraftment by the expanded unit in these prior studies. The first explanation is
that HSPCs that possess long-term repopulating ability are lost during the ex vivo culture
period. The second is that without coinfusion of immunocompetent T cells, the ability of the
expanded graft to compete successfully for long-term engraftment is lost.
The results of this trial provide justification for future studies to assess the safety and
feasibility of transplantation of NiCord as a single, expanded UCB unit. Not only does
NiCord expansion shorten the time to hematologic recovery, but it may also allow one to
choose a smaller but better HLA-matched UCB unit for transplantation. This has the potential
to mitigate the frequency and severity of GVHD and improve survival (6, 8, 9).
In summary, this study demonstrates that transplantation of UCB progenitor cells that are
cultured for 3 weeks using NiCord technology, along with a noncultured T cell fraction,
provide rapid short-term engraftment and stable long-term multilineage hematopoiesis.
Extended follow-up is needed to confirm the safety and durability of this cell product.
NiCord-expanded UCB has the potential to broaden the accessibility and reduce the toxicity
of UCB transplantation.
Patient and donor eligibility. Patients under the age of 65 years with hematologic malignancies and no available matched
sibling or matched unrelated adult donor were eligible at Duke University School of
Medicine or Loyola University Medical Center between December 2010 and August 2012.
Eligibility required the availability of 1 cord blood unit containing at least 2.5 ×
107 total nucleated cells per kilogram of the recipient’s body weight.
This unit was designated as the unmanipulated unit. The second unit, designated for NiCord
expansion, contained at least 1.5 × 107 total nucleated cells per kilogram
of the recipient’s body weight. When 2 units with at least 2.5 ×
107 total nucleated cells per kilogram of the recipient’s body weight
were available, the best-matched unit was assigned as the unmanipulated unit. The cord
blood units were required to match the recipient at 4 or more HLA loci by
intermediate-resolution typing for HLA class I alleles (A and B) and high-resolution
typing for HLA class II DRB1 alleles. A minimum level of matching between the 2 cord blood
units was not required. Cord blood units without cross-reactive donor-specific anti-HLA
antibodies were prioritized for selection, but were not required for protocol
NiCord production. The NiCord-designated (Gamida Cell) cryopreserved unit was delivered from the cord blood
bank to a cGMP-compliant cell-processing facility (Lonza). The unit was thawed on day
–21 of the stem cell transplantation and then underwent immunomagnetic bead
selection for CD133+ cells (Clinimacs; Miltenyi Biotec). Following CD133
selection, the CD133+ and CD34+ cell content of the negative
fraction was below 0.01% (data not shown). The CD133–, noncultured
fraction was cryopreserved and shipped to the transplant center in a dry shipper
maintained in a frozen state. Prior to cryopreservation, the cells were enumerated,
immunophenotyped, and tested for viability and safety (limulus amebocyte lysate [LAL]
endotoxin and sterility). The CD133+ fraction was tested for viability and
purity and then suspended in MEM α supplemented with 10% FBS, 50 ng per milliliter
each of Flt3 ligand, stem cell factor, thrombopoietin, IL-6 (R&D Systems), and 2.5
millimoles nicotinamide (Vertellus) at a concentration of 1 × 104 cells
per milliliter and seeded in culture bags (American Fluoroseal Corp.). The cultures were
supplemented weekly with fresh medium. After 21 ± 2 days of culture, the cells were
harvested, washed, and prepared for infusion in a transfusion PBS buffer. The fresh
product was hand-delivered to the transplant center at room temperature. Before release,
the final product was tested for total number of cells, colony-forming unit content, and
immunophenotype. Safety testing (gram staining, LAL endotoxin, and sterility) was
repeated. All products were infused within the stability specification of 18 hours. The
median time from harvest to infusion was 11.3 hours (range, 10–14 hours).
Transplantation approach. The bone marrow–conditioning regimen consisted of 1,350-cGy TBI delivered in 9
fractions on days –9 to –5, and fludarabine 40 mg/m2 was given on
days –5 to –2 of the transplantation. An optional infusion of 60 mg/kg
cyclophosphamide on days –4 and –3 was given at the discretion of the
managing physician. Infusion of the NiCord and unmanipulated grafts was separated by a
minimum of 2 hours and the infusion order alternated after every third patient. The
noncultured CD133– fraction of the NiCord graft was thawed on the day of
transplantation and infused after the cultured fraction. GVHD prophylaxis was provided by
tacrolimus and mycophenolate mofetil starting 4 days before transplantation. Mycophenolate
mofetil and tacrolimus were continued for a minimum of 60 days and 6 months following
transplantation, respectively. G-CSF (5 μg/kg of the recipient’s body weight)
was given daily starting on day 1 following transplantation until the absolute neutrophil
count exceeded 1,000 cells per microliter of blood. Patients were eligible for discharge
from the hospital when the absolute neutrophil count exceeded 500 cells per microliter of
Historical controls. Neutrophil, platelet, and immunologic recovery of study patients were compared with those
of a cohort of 17 patients who enrolled in a preceding phase II study at the Duke Adult
Blood and Marrow Transplant Program between April 2006 and January 2010 (14). To facilitate this analysis, we excluded patients
from this control cohort who experienced primary graft failure or toxic death before
engraftment. Patient characteristics are shown in Table 1. Patients received 2 unmanipulated UCB units each containing a minimum of 1.5
× 107 million nucleated cells per kilogram of the recipient’s body
weight. The cord blood units were required to match the recipient at 4 or more HLA loci by
intermediate-resolution typing for HLA class I alleles (A and B) and high-resolution
typing for HLA class II DRB1 alleles. A minimum level of matching between the 2 cord blood
units was not required. The presence of donor-specific anti-HLA antibodies was not
factored into the cord blood unit selection algorithm. The conditioning regimen, GVHD
prophylaxis, and supportive care measures (including use of G-CSF) were identical to those
of the current study cohort.
Laboratory and clinical assessments. Donor chimerism was performed on whole blood, CD15+ myeloid cells, and
CD3+ T cells using quantitative analysis of informative microsatellite DNA
sequences. Full donor chimerism was inferred when no detectable CD15+ myeloid
or CD3+ lymphoid bands were observed from either the host or the second UCB
unit. The time to neutrophil engraftment was defined as the first of 3 consecutive days
with an absolute neutrophil count of 0.5 × 109 per liter or higher and the
time to platelet engraftment as the first of 7 consecutive days with a platelet count of
20 × 109 per liter or higher without platelet transfusion. Chronic GVHD
was assessed using NIH consensus criteria.
Statistics. Comparisons of the median time to neutrophil and platelet engraftment, cord blood graft
characteristics, and hematologic recovery were performed using the Wilcoxon rank-sum test.
For the initial hospitalization duration assessment, patients who died before hospital
discharge were censored at the time of death, and patients who failed to engraft were
excluded. A P value less than or equal to 0.05 was considered
significant. Overall and event-free survival rates were estimated using the Kaplan-Meier
method. Events were defined as death, disease progression, or graft failure.
Study approval. The study was approved by the IRBs of both participating institutions and was conducted
under an IND from the US Food and Drug Administration. All patients provided written
informed consent. The study was conducted according to Declaration of Helsinki
View ICMJE disclosures
The authors thank the patients for their participation in the study. We acknowledge the
important contribution of the nurses and staff of the adult stem cell transplantation
programs at Duke University and Loyola University Medical Centers. We give special thanks to
Ann Kaestner and Tiffany Bradshaw of the Duke Stem Cell Laboratory for their contribution in
preparing the UCB units for transplantation. The trial was funded by Gamida Cell Ltd. This
work was supported in part by grants from the National Cancer Institute, NIH
(P01-CA047741-19, to M.E. Horwitz, N.J. Chao, and D.A. Rizzieri).
Conflict of interest: Mitchell E. Horwitz has received research support from
Gamida Cell, Sanofi, and Pfizer. Joanne Kurtzberg is a medical advisor for the National
Marrow Donor Program Center for Cord Blood and StemCyte Cord Blood Bank, medical director
of the Carolinas Cord Blood Bank and CORD:USE Cord Blood Bank, a member of the FACT board
of directors, and a member of the Advisory Council of Blood Stem Cell Transplantation
(Department of Health and Human Services). Tony Peled, David Snyder, Einat Galamidi Cohen,
Hadas Shoham, Efrat Landau, Etty Friend, Iddo Peleg, Dorit Aschengrau, and Dima Yackoubov
are employees of Gamida Cell.
Note regarding evaluation of this manuscript: Manuscripts authored by
scientists associated with Duke University, The University of North Carolina at Chapel
Hill, Duke-NUS, and the Sanford-Burnham Medical Research Institute are handled not by
members of the editorial board but rather by the science editors, who consult with
selected external editors and reviewers.
Citation for this article:J Clin Invest.
Brown JA, et al. Clearance of CMV viremia and survival after double umbilical cord blood
transplantation in adults depends on reconstitution of thymopoiesis. Blood. 2010;115(20):4111–4119.
Kanda J, et al. Immune recovery in adult patients after myeloablative dual umbilical cord
blood, matched sibling, and matched unrelated donor hematopoietic cell
transplantation. Biol Blood Marrow Transplant. 2012;18(11):1664–1676.
Laughlin MJ, et al. Hematopoietic engraftment and survival in adult recipients of
umbilical-cord blood from unrelated donors. N Engl J Med. 2001;344(24):1815–1822.
Rocha V, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in
adults with acute leukemia. N Engl J Med. 2004;351(22):2276–2285.
Brunstein CG, et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy:
relative risks and benefits of double umbilical cord blood. Blood. 2010;116(22):4693–4699.
Eapen M, et al. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes
after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a
retrospective analysis. Lancet Oncol. 2011;12(13):1214–1221.
Eapen M, et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in
children with B-precursor acute lymphoblastic leukemia in a second remission: a
collaborative study of the Children’s Oncology Group and the Center for
International Blood and Marrow Transplant Research. Blood. 2006;107(12):4961–4967.
Barker JN, Scaradavou A, Stevens CE. Combined effect of total nucleated cell dose and HLA match on
transplantation outcome in 1061 cord blood recipients with hematologic
malignancies. Blood. 2010;115(9):1843–1849.
Eapen M, et al. Impact of allele-level HLA matching on outcomes after myeloablative single
unit umbilical cord blood transplantation for hematologic malignancy. Blood. 2014;123(1):133–140.
Scaradavou A, et al. Double unit grafts successfully extend the application of umbilical cord
blood transplantation in adults with acute leukemia. Blood. 2013;121(5):752–758.
Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID. Notch-mediated expansion of human cord blood progenitor cells capable of
rapid myeloid reconstitution. Nat Med. 2010;16(2):232–236.
de Lima M, et al. Cord-blood engraftment with ex vivo mesenchymal-cell
coculture. N Engl J Med. 2012;367(24):2305–2315.
Peled T, et al. Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and facilitates
expansion of hematopoietic progenitor cells with enhanced bone marrow homing and
engraftment. Exp Hematol. 2012;40(4):342–355.
Kanda J, et al. Adult dual umbilical cord blood transplantation using myeloablative total
body irradiation (1350 cGy) and fludarabine conditioning. Biol Blood Marrow Transplant. 2011;17(6):867–874.
Brunstein CG, et al. Umbilical cord blood transplantation after nonmyeloablative conditioning:
impact on transplantation outcomes in 110 adults with hematologic
disease. Blood. 2007;110(8):3064–3070.
Barker JN, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to
enhance engraftment in adults with hematologic malignancy. Blood. 2005;105(3):1343–1347.
Gutman JA, et al. Single-unit dominance after double-unit umbilical cord blood
transplantation coincides with a specific CD8+ T-cell response against the
nonengrafted unit. Blood. 2010;115(4):757–765.
Moretta A, et al. In vitro evaluation of graft-versus-graft alloreactivity as a tool to
identify the predominant cord blood unit before double cord blood
transplantation. Biol Blood Marrow Transplant. 2012;18(7):1108–1118.
Klein AK, et al. T-Cell recovery in adults and children following umbilical cord blood
transplantation. Biol Blood Marrow Transplant. 2001;7(8):454–466.
Mackall CL, et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive
chemotherapy. N Engl J Med. 1995;332(3):143–149.
Anjos-Afonso F, Currie E, Palmer HG, Foster KE, Taussig DC, Bonnet D. CD34(–) cells at the apex of the human hematopoietic stem cell
hierarchy have distinctive cellular and molecular signatures. Cell Stem Cell. 2013;13(2):161–174.
Bhatia M, Bonnet D, Murdoch B, Gan OI, Dick JE. A newly discovered class of human hematopoietic cells with
SCID-repopulating activity. Nat Med. 1998;4(9):1038–1045.